Advertisement

Urological Research

, Volume 25, Issue 1, pp 1–8 | Cite as

Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer

  • T. J. O. Liukkonen
  • P. K. Lipponen
  • M. Helle
  • K. E. Jauhiainen
  • Finnbladder III Groups
Original Papers

Abstract

Immunoreactivity of bcl-2, p53, the epidermal growth factor (EGFr) and Ki-67 (MIB-1) proteins was assessed by immunohistochemistry in 185 patients with superficial bladder cancer (SBC) in order to evaluate their usefulness as indicators of tumor progression. Forty-one percent of the tumors were bcl-2 positive, 36% of them were positive for p53 (over 20% of nuclei), while 41% were positive for EGFr, and 30% of the tumors were MIB-1 positive (proliferation index > 15%). Immunoreactivity of all analyzed proteins was highly significantly related to tumor grade and stage. Tumors which were bcl-2, p53 or EGFr positive were also rapidly proliferative (MIB-1 score > 15%). The obtained results suggest that all analyzed proteins may have prognostic significance in SBC. The prognostic value of the abnormal immunolabeling of the analyzed proteins will be established after an adequate follow-up period of this same cohort of patients.

Key words

Superficial bladder cancer bcl-2 p53 EGFr MIB-1 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allan DJ, Howell A, Roberts SA, Williams GT, Watson RJ, Coyne JD, Clarke RB, Laidlaw IJ, Porten CS (1992) Reduction of apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 167:25Google Scholar
  2. 2.
    Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:921Google Scholar
  3. 3.
    Barbareschi M, Iuzzolino P, Pennella A, Allegranza A, Arrigoni G, Dalla-Palma P, Doglioni C (1992) p53 protein expression in central nervous system neoplasms. J Clin Pathol 45:583Google Scholar
  4. 4.
    Brown DC, Gatter KC0 (1990) Monoclonal antibody Ki-67:its use in histopathology. Histopathology 17:489Google Scholar
  5. 5.
    Cattoretti G, Becker MHG, Key G, Duchrow M Schlüter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357Google Scholar
  6. 6.
    Cohen S (1983) The epidermal growth factor. Cancer 51:1787Google Scholar
  7. 7.
    Desoize B (1994) Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14:2291Google Scholar
  8. 8.
    Esrig D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen S-C, Skinner DG, Jones PA, Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 143:1389Google Scholar
  9. 9.
    Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259Google Scholar
  10. 10.
    Gerdes J (1990) Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. In: Osborn M (ed) Cancer biology, vol 1. Saunders Scientific Publications, London p 99Google Scholar
  11. 11.
    Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095Google Scholar
  12. 12.
    Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann D, Hawkins IR and National Bladder Cancer Collaborative Group A (1983) Superficial bladder cancer: Progression and recurrence. J Urol 130:1083Google Scholar
  13. 13.
    Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716Google Scholar
  14. 14.
    Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109Google Scholar
  15. 15.
    Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191Google Scholar
  16. 16.
    Key G, Becker MHG, Duchrow M, Schluter C, Gerdes J (1992) New Ki-67 equivalent murine monoclonal antibodies (MIB-13) prepared against recombinant parts of the Ki-67 antigen. Anal Cell Pathol 4:181Google Scholar
  17. 17.
    Kiemeney LALM, Witjes JA, Verbeek ALM, Heijbroek RP, Debruyne FMJ and members of the Dutch South-East Cooperative Urological Group (1993) The clinical epidemiology of superficial bladder cancer. Br J Cancer 67:806Google Scholar
  18. 18.
    Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla-Palma P, Barbareschi M (1992) PCNA and Ki-67 expression in breast carcinoma: Correlations with clinical and biological variables. J Clin Pathol 45:416Google Scholar
  19. 19.
    Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erB-2, p53) expression and long-term prognosis. Br J Cancer 69:1120Google Scholar
  20. 20.
    Lipponen PK, Liukkonen TJ (1995) Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional cell bladder cancer. J Cancer Res Clin Oncol 121:44Google Scholar
  21. 21.
    Lipponen PK, Nordling S, Eskelinen MJ, Jauhiainen KJ, Terho R, Harju E (1993) Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional cell bladder cancer. Int J Cancer 53:42Google Scholar
  22. 22.
    Lotem J, Sachs L (1993) Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentation-competent and -defective myeloid leukemic cells. Cell Growth Differ 3:41Google Scholar
  23. 23.
    Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957Google Scholar
  24. 24.
    Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM (1994) p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 25:1346Google Scholar
  25. 25.
    Mostofi FK, Sobin LH, Torloni H (1973) International histological classification of tumours. In: Mostofi FL, Sobin LH, Torloni H (eds) No. 10 Histological typing of urinary bladder tumours, WHO, GenevaGoogle Scholar
  26. 26.
    Neat DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619Google Scholar
  27. 27.
    Ooms ECM, Andersson WAD, Alons CL, Veldhuizen RW, Boon ME (1983) An analysis of the performance of pathologists in grading bladder tumors. Hum Pathol 14:140Google Scholar
  28. 28.
    Pignatelii M, Stamp GW, Kafiri G, Lane D, Bodmer WF (1992) Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50:683Google Scholar
  29. 29.
    Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F (1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337Google Scholar
  30. 30.
    Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1Google Scholar
  31. 31.
    Sachs L, Lotem J (1993) Control of programmed cell death in normal and leucemic cells: new implications for therapy. Blood 82:15Google Scholar
  32. 32.
    Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helen HJ (1994) Prognostication of astrocytoma patient survival by Ki-67(MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275Google Scholar
  33. 33.
    Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85:53Google Scholar
  34. 34.
    Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mihatsch MJ, Waldman F (1994) Epidermal growth factor receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 57:508Google Scholar
  35. 35.
    Scott N, Sagar P, Stewart J, Blair GE, Dixon ME, Quirke P (1991) p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br J Cancer 63:317Google Scholar
  36. 36.
    Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B (1995) bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237Google Scholar
  37. 37.
    Steinmeyer K, Deppert W (1988) DNA binding properties of murine p53. Oncogene 3:501Google Scholar
  38. 38.
    Szende B, Juhasz E, Lapis K, Schally AV (1992) Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Urol Res 20:383Google Scholar
  39. 39.
    Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214Google Scholar
  40. 40.
    UICC (1978) International Union Against Cancer, TNM classification of malignant tumours. UICC, GenevaGoogle Scholar
  41. 41.
    Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, Bergholm U, Coggi G (1995) Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 26:245Google Scholar
  42. 42.
    Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883Google Scholar
  43. 43.
    Wang Y, Szekely L, Okan I, Klein G, Wiman KG (1993) Wildtype p53-triggered apoptosis is inhibited by bcl-2 in a v-mycinduced T-cell lymphoma cell line. Oncogene 8:3427Google Scholar
  44. 44.
    Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CHW, Neal DE (1991) Expression of mutant p53, c-erB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63:967Google Scholar
  45. 45.
    Wyllie AH (1985) The biology of cell death in tumors. Anticancer Res 5:131Google Scholar
  46. 46.
    Zhu Y-M, Bradbury DA, Russell NH (1994) Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69:468Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • T. J. O. Liukkonen
    • 1
  • P. K. Lipponen
    • 2
  • M. Helle
    • 3
  • K. E. Jauhiainen
    • 1
  • Finnbladder III Groups
  1. 1.Department of SurgeryMikkeli Central HospitalMikkeliFinland
  2. 2.Department of PathologyUniversity of KuopioFinland
  3. 3.Department of PathologyMikkeli Central HospitalMikkeliFinland

Personalised recommendations